Valuable New Prognostic Scoring System in Patients with CML Receiving Nilotinib as Initial Treatment
Outcomes in patients with chronic myeloid leukemia (CML) have significantly improved after the introduction of tyrosine kinase inhibitors (TKIs). To facilitate discrimination of patients’ probability of dying of CML or other causes, the European LeukemiaNet recently published a new scoring system, EUTOS long-term survival (ELTS). This score was based on CML patients who were initially treated with imatinib. Researchers report findings from a study that evaluated the prognostic value of ELTS score in CML patients who were treated with nilotinib, a second-generation TKI.
Ibrutinib Results in Robust Clinical Activity and Survival Outcomes in Difficult-to-Treat CLL Populations
Patients with deletion 17p chronic lymphocytic leukemia (CLL) have aggressive disease and poor outcomes with chemoimmunotherapy. Ibrutinib, a once-daily therapy that inhibits Bruton’s tyrosine kinase, is approved for previously untreated patients with CLL, including patients with deletion 17p. This cross-study analysis of efficacy and tolerability outcomes for ibrutinib reports 2+-year data in this high-risk subset of patients.
Acalabrutinib is a second-generation inhibitor of Bruton’s tyrosine kinase (BTK) that is currently being evaluated in patients with previously untreated and relapsed chronic lymphocytic leukemia (CLL), as well as other hematologic malignancies. Researchers report phase 1/2 study results for acalabrutinib, including overall response rates, rates of treatment-related lymphocytosis, bleeding risk, and other safety details.
Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study
Ibrutinib, an inhibitor of Bruton’s tyrosine kinase, is approved for use as monotherapy in patients with treatment-naïve and relapsed chronic lymphocytic leukemia (CLL). Studies of ibrutinib in combination with other agents are underway. Follow-up data from a large phase 3 study of ibrutinib + BR versus BR in relapsed CLL have now reached the 2-year point.
Chimeric antigen receptor (CAR)-modified T cells are emerging as an effective and safe therapy for children and young adults with acute lymphoblastic leukemia (ALL). This study assesses CD19 CAR T cells in pediatric patients with ALL, including patients with a history of central nervous system (CNS) involvement.
Overall Survival Benefit in Relapsed and Refractory B-Cell ALL Patients Receiving Inotuzumab Ozogamicin
Inotuzumab ozogamicin (InO), a humanized anti-CD22 antibody conjugated to calicheamicin, has demonstrated superior responses compared with chemotherapy in patients with relapsed and refractory acute lymphoblastic leukemia (ALL) in a phase 3 trial known as INO-VATE. In this late-breaking presentation, researchers report overall survival and progression-free survival findings for InO relative to chemotherapy.
Anthracycline and Ara-C have been standard induction agents for acute myeloid leukemia (AML) for 30 years. Several trials comparing 90 mg/m2 of daunorubicin with 45 mg/m2 have found either overall benefits or benefit in specific patient subgroups, such as FLT3-ITD–mutant patients. This analysis confirms the value of higher-dose daunorubicin after a median follow-up of 2+ years.
Outcomes Associated with Conventional Salvage Therapy in Patients with Refractory or Relapsed AML and IDH1/IDH2 Mutations
Somatic mutations affecting isocitrate dehydrogenase 1 (IDH1) or 2 (IDH2) genes are found in 15% to 20% of patients with acute myeloid leukemia (AML), with incidence increasing in older patients. These mutated enzymes represent therapeutic targets, and selective inhibitors of IDH1 and IDH2 are in early-phase development. This study assessed differences in outcomes for patients with relapsed AML and IDH1/IDH2 mutations.
Response-Adapted Sequential Azacitidine and Intensive Chemotherapy Is Effective in Patients Aged >60 Years with Newly Diagnosed AML
Treatment options for acute myeloid leukemia (AML) in patients aged >60 years include intensive chemotherapy (IC) and azacitidine (AZA). The multicenter RAS-AZIC study of the East German Study Group (OSHO), evaluated first-line treatment with AZA followed by AZA or IC in these patients. Data from the planned interim analysis are presented.
Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem-Cell Transplantation for De Novo ALL in Adults
Allogeneic hematopoietic stem-cell transplantation (alloHSCT) is a potentially curable treatment modality for adults with acute lymphoblastic leukemia (ALL), offering significant improvement in survival and reduction in relapse incidence. This approach is limited, however, by toxicity and early mortality. Researchers report outcomes of patients who received RIC followed by alloHSCT in the UKALL14 trial.
Page 1 of 30
Results 1 - 10 of 294
Results 1 - 10 of 294